MedPath

福建盛迪医药有限公司

Ownership
-
Established
2018-07-16
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

7

NMPA:7

Drug Approvals

Fosrolapitant and Palonosetron Hydrochloride for Injection

Product Name
瑞坦宁
Approval Number
国药准字H20250027
Approval Date
May 27, 2025
NMPA

Hemofiltration Replacement Fluid of Sodium Citrate

Product Name
枸橼酸钠血滤置换液
Approval Number
国药准字H20254278
Approval Date
May 27, 2025
NMPA

Compound Amino Acid (16AA), Glucose (12.6%) and Electrolyte Injection

Product Name
复方氨基酸(16AA)/葡萄糖(12.6%)电解质注射液
Approval Number
国药准字H20253130
Approval Date
Jan 14, 2025
NMPA

10% Fat Emulsion (OO)/5.5% Amino Acids (15)/Glucose (20%) Injection

Product Name
10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液
Approval Number
国药准字H20234621
Approval Date
Dec 13, 2023
NMPA

Paracetamol and Mannitol Injection

Product Name
对乙酰氨基酚甘露醇注射液
Approval Number
国药准字H20223028
Approval Date
Jan 30, 2022
NMPA

Sodium Potassium and Glucose Injection

Product Name
钠钾葡萄糖注射液
Approval Number
国药准字H20217008
Approval Date
Jan 14, 2021
NMPA

Sodium Potassium and Glucose Injection

Product Name
钠钾葡萄糖注射液
Approval Number
国药准字H20217007
Approval Date
Jan 14, 2021
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.